APCR
0.004
300%
IMC
0.039
-40%
MEU
0.12
71.4%
JNS
0.058
-38.9%
IFG
0.017
70%
TMB
0.049
-34.7%
VRC
0.01
66.7%
MIO
0.02
-33.3%
ALV
0.085
63.5%
PET
0.014
-30%
CTN
0.003
50%
CRS
0.091
-27.2%
IMM
0.375
47.1%
DTM
0.035
-27.1%
PER
0.01
42.9%
BAP
1.76
-25.1%
AUA
0.04
37.9%
NES
0.006
-25%
STV
0.011
37.5%
A11
0.155
-24.4%
ELS
2.67
35.5%
WNX
0.125
-24.2%
AGY
0.095
33.8%
AM5
0.007
-22.2%
ALY
0.012
33.3%
KLV
0.007
-22.2%
CHM
0.004
33.3%
NFL
0.11
-21.4%
RHY
0.105
32.9%
MNB
0.023
-20.7%
AR9
0.13
32.7%
CKA
0.054
-20.6%
ASL
2.43
31.4%
HVY
0.5
-20%
X2M
0.013
30%
TYX
0.004
-20%
LRM
0.031
29.2%
LKY
0.205
-19.6%
SPD
1.565
28.8%
SUM
0.033
-19.5%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

CMH Clinical trial openfor enrollment

Chimeric Therapeutics (ASX:CHM), Australian leader in cell therapy, announces the Phase 18 ADVENT-AML clinical trial for patients with newly diagnosed Acute Myeloid Leukaemia is now open to enrolment at The University of Texas MD Anderson Cancer Center https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02762504-2A1499759